tifluadom has been researched along with guanosine 5'-o-(3-thiotriphosphate) in 1 studies
| Studies (tifluadom) | Trials (tifluadom) | Recent Studies (post-2010) (tifluadom) | Studies (guanosine 5'-o-(3-thiotriphosphate)) | Trials (guanosine 5'-o-(3-thiotriphosphate)) | Recent Studies (post-2010) (guanosine 5'-o-(3-thiotriphosphate)) |
|---|---|---|---|---|---|
| 78 | 0 | 0 | 5,542 | 8 | 368 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heyliger, SO; Jackson, C; Rice, KC; Rothman, RB | 1 |
1 other study(ies) available for tifluadom and guanosine 5'-o-(3-thiotriphosphate)
| Article | Year |
|---|---|
Opioid peptide receptor studies. 10. Nor-BNI differentially inhibits kappa receptor agonist-induced G-protein activation in the guinea pig caudate: further evidence of kappa receptor heterogeneity.
Topics: Animals; Benzeneacetamides; Benzodiazepines; Brain; Caudate Nucleus; Dose-Response Relationship, Drug; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Guinea Pigs; In Vitro Techniques; Inhibitory Concentration 50; Naltrexone; Oligopeptides; Peptide Fragments; Peptides; Pyrrolidines; Rats; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Somatostatin | 1999 |